Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Hurt

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Transactions of the Royal Society of Tropical Medicine and Hygiene|March 1, 1994
Evaluation of C-reactive protein and haptoglobin as malaria episode markers in an area of high transmission in AfricaN Hurt, T Smith, M Tanner, et al.
Clinical and Experimental Immunology|April 1, 1995
Immunological markers of childhood fevers in an area of intense and perennial malaria transmissionN Hurt, M Thein, T Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2017
Human Papillomavirus DNA Methylation Predicts Response to Treatment Using Cidofovir and Imiquimod in Vulval Intraepithelial Neoplasia 3Sadie E F Jones, Samantha Hibbitts, Christopher N Hurt, et al.
Molecular and Cellular Biology|November 1, 1989
cDNA structures and regulation of two interferon-induced human Mx proteinsM Aebi, J Fäh, N Hurt, et al.
Journal of Patient-Reported Outcomes|July 9, 2024
Content validation of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFLymSI-18) in indolent B-cell non-Hodgkin's lymphomaCourtney N Hurt, Karen Kaiser, Sara Shaunfield, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|January 17, 2018
Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multicentre, randomised, phase II trial (RT3VIN)C N Hurt, Sef Jones, T-A Madden, et al.
Clinical and Experimental Rheumatology|July 30, 2025
A co-produced patient-reported outcomes-driven dashboard to support shared decision-making in rheumatologic diseases: a feasibility studyMaja Kuharic, Courtney N Hurt, George J Greene, et al.
Infection and Immunity|December 22, 1999
Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3M Aidoo, A Lalvani, S C Gilbert, et al.
Vaccine|March 1, 1994
SPf66, a chemically synthesized subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmissionT Teuscher, J R Schellenberg, I Bastos de Azevedo, et al.
British Journal of Cancer|April 5, 2017
Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancerC N Hurt, S Falk, T Crosby, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Transactions of the Royal Society of Tropical Medicine and Hygiene|March 1, 1994
Evaluation of C-reactive protein and haptoglobin as malaria episode markers in an area of high transmission in AfricaN Hurt, T Smith, M Tanner, et al.
Clinical and Experimental Immunology|April 1, 1995
Immunological markers of childhood fevers in an area of intense and perennial malaria transmissionN Hurt, M Thein, T Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2017
Human Papillomavirus DNA Methylation Predicts Response to Treatment Using Cidofovir and Imiquimod in Vulval Intraepithelial Neoplasia 3Sadie E F Jones, Samantha Hibbitts, Christopher N Hurt, et al.
Molecular and Cellular Biology|November 1, 1989
cDNA structures and regulation of two interferon-induced human Mx proteinsM Aebi, J Fäh, N Hurt, et al.
Journal of Patient-Reported Outcomes|July 9, 2024
Content validation of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFLymSI-18) in indolent B-cell non-Hodgkin's lymphomaCourtney N Hurt, Karen Kaiser, Sara Shaunfield, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|January 17, 2018
Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multicentre, randomised, phase II trial (RT3VIN)C N Hurt, Sef Jones, T-A Madden, et al.
Clinical and Experimental Rheumatology|July 30, 2025
A co-produced patient-reported outcomes-driven dashboard to support shared decision-making in rheumatologic diseases: a feasibility studyMaja Kuharic, Courtney N Hurt, George J Greene, et al.
Infection and Immunity|December 22, 1999
Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3M Aidoo, A Lalvani, S C Gilbert, et al.
Vaccine|March 1, 1994
SPf66, a chemically synthesized subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmissionT Teuscher, J R Schellenberg, I Bastos de Azevedo, et al.
British Journal of Cancer|April 5, 2017
Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancerC N Hurt, S Falk, T Crosby, et al.
Pageof 5